NCT06916975

Adebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer

A Prospective, Single-Arm, Phase II Clinical Trial of Adebrelimab Combined With AG Regimen in Patients With Unresectable Locally Advanced or Metastatic Pancreatic Cancer

• Status: Not Yet Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 46 (estimated)
• Sponsor: Jin Xu · Academic / Other
• Sex: All
• Age: 18 Years – 75 Years
• Healthy volunteers: Not accepted

Summary

This study aims to evaluate the efficacy and safety of adebrelimab combined with the AG regimen in patients with unresectable locally advanced or metastatic pancreatic cancer who have received at least one prior line of systemic therapy but have not undergone gemcitabine-based treatment.

Conditions

• Pancreatic Cancer Non-resectable
• Pancreatic Cancer Metastatic

Interventions

Type	Name	Description
DRUG	Adebrelimab	Adebrelimab: 1200mg，iv，d1，q3w；
DRUG	AG	Gemcitabine: 1000 mg/m² ，iv，d1、d8，q3w； Nab-paclitaxel: 125 mg/m² ，iv，d1、d8，q3w；

Timeline

• Start date: 2025-04-15
• Primary completion: 2027-12-01
• Completion: 2028-12-01
• First posted: 2025-04-08
• Last updated: 2025-04-08

Locations

1 site across 1 country: China